Table 2. Summary results for status quo scenario and the expanded access scenario.

Results show the median and interquartile range (IQR) of all simulations for each scenario. ART, antiretroviral treatment; NA, not applicable. Costs are, rounded to the nearest A$10 000

Indicator	Status quo scenario (median, IQR)	Expanded access scenario (median, IQR)
Annual infections after 5 years	22 (18–26)	5 (3–7)
Cumulative infections	131 (116–145)	50 (42–57)
Infections averted	NA	80 (68–91)
Cost of providing care and ART (undiscounted)	NA	A$40 820 000 (A$34 110 000-A$47 530 000)
Lifetime care and ART costs (undiscounted)	A$131 620 000 (A$111 230 000–A$152020 000)	A$50 570 000 (A$41450 000-A$59 700 000)
Reduction in lifetime care and ART costs (undiscounted)	NA	A$80 570 000(A$65 840 000-A$95 310 000)
Cost of providing care and ART (discounted 5%)	NA	A$36 240 000(A$30 280 000-A$42 200 000)
Lifetime care and ART costs (discounted 5%)	A$36640000 ($A31 490 000–A$41780000)	A$14 720 000 (A$12 300 000-A$17 140 000)
Reduction in lifetime care and ART costs (discounted 5%)	NA	A$21 730 000 (A$17 930 000-A$25 530 000)